{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T08:52:58Z","timestamp":1775465578737,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,6]]},"DOI":"10.7759\/cureus.106502","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T08:01:14Z","timestamp":1775462474000},"source":"Crossref","is-referenced-by-count":0,"title":["Feasibility of Outpatient Follow-Up After High-Dose Cytarabine Consolidation in Patients With Acute Myeloid Leukemia"],"prefix":"10.7759","author":[{"given":"Md Foys","family":"Ullah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Md Gulam","family":"Kibria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazi Fazlur","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Md Zakaria","family":"Hossen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nahid","family":"Sultana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amin Lutful","family":"Kabir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akhil Ranjan","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.29328\/journal.jsctt.1001038","article-title":"The outcome of outpatient intermediate and high dose cytarabine consolidation chemotherapy in patients with acute myeloid leukemia. The experience of King Fahad Specialist Hospital in Dammam, Saudi Arabia","volume":"8","author":"Al-Anazi KA","year":"2024","unstructured":"Al-Anazi KA, Alsaeed NJ, Kanfer S, et al.. The outcome of outpatient intermediate and high dose cytarabine consolidation chemotherapy in patients with acute myeloid leukemia. The experience of King Fahad Specialist Hospital in Dammam, Saudi Arabia. J Stem Cell Ther Transplant. 2024, 8:16-28. 10.29328\/journal.jsctt.1001038","journal-title":"J Stem Cell Ther Transplant"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01424-6","article-title":"Recent advances in targeted therapies in acute myeloid leukemia","volume":"16","author":"Bhansali RS","year":"2023","unstructured":"Bhansali RS, Pratz KW, Lai C. Recent advances in targeted therapies in acute myeloid leukemia. J Hematol Oncol. 2023, 16:29. 10.1186\/s13045-023-01424-6","journal-title":"J Hematol Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26822","article-title":"Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management","volume":"98","author":"Shimony S","year":"2023","unstructured":"Shimony S, Stahl M, Stone RM. Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023, 98:502-26. 10.1002\/ajh.26822","journal-title":"Am J Hematol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14194756","article-title":"Updates on the management of acute myeloid leukemia","volume":"14","author":"Huerga-Dom\u00ednguez S","year":"2022","unstructured":"Huerga-Dom\u00ednguez S, Villar S, Pr\u00f3sper F, Alfonso-Pi\u00e9rola A. Updates on the management of acute myeloid leukemia. Cancers (Basel). 2022, 14:4756. 10.3390\/cancers14194756","journal-title":"Cancers (Basel)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-01884-2","article-title":"Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia","volume":"37","author":"Rausch C","year":"2023","unstructured":"Rausch C, Rothenberg-Thurley M, Dufour A, et al.. Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia. Leukemia. 2023, 37:1234-44. 10.1038\/s41375-023-01884-2","journal-title":"Leukemia"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner H","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, et al.. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022, 140:1345-77. 10.1182\/blood.2022016867","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-017-0456-2","article-title":"Treatment of relapsed\/refractory acute myeloid leukemia","volume":"18","author":"Bose P","year":"2017","unstructured":"Bose P, Vachhani P, Cortes JE. Treatment of relapsed\/refractory acute myeloid leukemia. Curr Treat Options Oncol. 2017, 18:17. 10.1007\/s11864-017-0456-2","journal-title":"Curr Treat Options Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15458","article-title":"Phase I study of alvocidib plus cytarabine\/mitoxantrone or cytarabine\/daunorubicin for acute myeloid leukemia in Japan","volume":"113","author":"Ikezoe T","year":"2022","unstructured":"Ikezoe T, Ando K, Onozawa M, et al.. Phase I study of alvocidib plus cytarabine\/mitoxantrone or cytarabine\/daunorubicin for acute myeloid leukemia in Japan. Cancer Sci. 2022, 113:4258-66. 10.1111\/cas.15458","journal-title":"Cancer Sci"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-013-1882-2","article-title":"Breakthrough invasive fungal diseases during echinocandin treatment in high-risk hospitalized hematologic patients","volume":"93","author":"Chan TS","year":"2014","unstructured":"Chan TS, Gill H, Hwang YY, et al.. Breakthrough invasive fungal diseases during echinocandin treatment in high-risk hospitalized hematologic patients. Ann Hematol. 2014, 93:493-8. 10.1007\/s00277-013-1882-2","journal-title":"Ann Hematol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-011-1223-2","article-title":"Clofarabine and high-dose cytosine arabinoside in the treatment of refractory or relapsed acute myeloid leukaemia","volume":"90","author":"Tse E","year":"2011","unstructured":"Tse E, Leung AY, Sim J, Lee HK, Liu HS, Yip SF, Kwong YL. Clofarabine and high-dose cytosine arabinoside in the treatment of refractory or relapsed acute myeloid leukaemia. Ann Hematol. 2011, 90:1277-81. 10.1007\/s00277-011-1223-2","journal-title":"Ann Hematol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML","volume":"378","author":"DiNardo CD","year":"2018","unstructured":"DiNardo CD, Stein EM, de Botton S, et al.. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med. 2018, 378:2386-98. 10.1056\/NEJMoa1716984","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo CD","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, et al.. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020, 383:617-29. 10.1056\/NEJMoa2012971","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199410063311402","article-title":"Intensive postremission chemotherapy in adults with acute myeloid leukemia","volume":"331","author":"Mayer RJ","year":"1994","unstructured":"Mayer RJ, Davis RB, Schiffer CA, et al.. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med. 1994, 331:896-903. 10.1056\/NEJM199410063311402","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33477","article-title":"Acute myeloid leukemia: treatment and research outlook for 2021 and the MD Anderson approach","volume":"127","author":"Kantarjian HM","year":"2021","unstructured":"Kantarjian HM, Kadia TM, DiNardo CD, Welch MA, Ravandi F. Acute myeloid leukemia: treatment and research outlook for 2021 and the MD Anderson approach. Cancer. 2021, 127:1186-207. 10.1002\/cncr.33477","journal-title":"Cancer"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V122.21.2692.2692","article-title":"High-dose cytarabine consolidation (\u22651.5 g\/m2) might have shown a better outcomes than intermediate-dose cytarabine (1.0 g\/m2) combined with anthracyclines in AML patients who had achieved complete remissions in the first induction by standard 3+7 regimen","volume":"122","author":"Park Y","year":"2013","unstructured":"Park Y, Kang G, Kim DS, et al.. High-dose cytarabine consolidation (\u22651.5 g\/m2) might have shown a better outcomes than intermediate-dose cytarabine (1.0 g\/m2) combined with anthracyclines in AML patients who had achieved complete remissions in the first induction by standard 3+7 regimen. Blood. 2013, 122:2692. 10.1182\/blood.V122.21.2692.2692","journal-title":"Blood"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5704","article-title":"Prognostication refinement in NPM1-mutated acute myeloid leukemia stratified by FLT3-ITD status with different induction doses of cytarabine","volume":"12","author":"Wang B","year":"2023","unstructured":"Wang B, Hua X, Zhang J, Gu W, Li H. Prognostication refinement in NPM1-mutated acute myeloid leukemia stratified by FLT3-ITD status with different induction doses of cytarabine. Cancer Med. 2023, 12:9420-33. 10.1002\/cam4.5704","journal-title":"Cancer Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.45","article-title":"Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia","volume":"7","author":"Jaramillo S","year":"2017","unstructured":"Jaramillo S, Benner A, Krauter J, et al.. Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia. Blood Cancer J. 2017, 7:e564. 10.1038\/bcj.2017.45","journal-title":"Blood Cancer J"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-025-06551-3","article-title":"Clinical outcomes with high dose cytarabine and idarubicin consolidation for adult AML patients","volume":"104","author":"Qian B","year":"2025","unstructured":"Qian B, Huang G, Cai X, Liu Y, Li D, Yin J. Clinical outcomes with high dose cytarabine and idarubicin consolidation for adult AML patients. Ann Hematol. 2025, 104:4539-47. 10.1007\/s00277-025-06551-3","journal-title":"Ann Hematol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.70024","article-title":"Outpatient cytarabine consolidation in acute myeloid leukemia safely reduces hospitalization time and treatment costs","volume":"131","author":"Burton H","year":"2025","unstructured":"Burton H, Boussi L, Nemirovsky D, et al.. Outpatient cytarabine consolidation in acute myeloid leukemia safely reduces hospitalization time and treatment costs. Cancer. 2025, 131:e70024. 10.1002\/cncr.70024","journal-title":"Cancer"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.70024","article-title":"Plasma profiling of acute myeloid leukemia with fever- and infection-related complications during chemotherapy-induced neutropenia","volume":"7","author":"Kreft IC","year":"2024","unstructured":"Kreft IC, van de Geer A, Smit ER, et al.. Plasma profiling of acute myeloid leukemia with fever- and infection-related complications during chemotherapy-induced neutropenia. Cancer Rep (Hoboken). 2024, 7:e70024. 10.1002\/cnr2.70024","journal-title":"Cancer Rep (Hoboken)"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.2061","article-title":"High throughput screening aids clinical decision-making in refractory acute myeloid leukaemia","volume":"7","author":"Jessop SJ","year":"2024","unstructured":"Jessop SJ, Fuentos-Bolanos N, Mayoh C, et al.. High throughput screening aids clinical decision-making in refractory acute myeloid leukaemia. Cancer Rep (Hoboken). 2024, 7:e2061. 10.1002\/cnr2.2061","journal-title":"Cancer Rep (Hoboken)"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.2010.02201.x","article-title":"Randomized cross-over trial comparing inpatient and outpatient administration of high-dose cisplatin","volume":"41","author":"Cox KM","year":"2011","unstructured":"Cox KM, Goel S, O'Connell RL, Boyer M, Beale PJ, Simes RJ, Stockler MR. Randomized cross-over trial comparing inpatient and outpatient administration of high-dose cisplatin. Intern Med J. 2011, 41:172-8. 10.1111\/j.1445-5994.2010.02201.x","journal-title":"Intern Med J"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.18502\/ijhoscr.v14i3.3722","article-title":"Safety and feasibility of outpatient high dose cytarabine for acute myeloid leukemia in the Brazilian Amazon","volume":"14","author":"Rodrigues AL","year":"2020","unstructured":"Rodrigues AL, do Nascimento DM, de Lima JM, et al.. Safety and feasibility of outpatient high dose cytarabine for acute myeloid leukemia in the Brazilian Amazon. Int J Hematol Oncol Stem Cell Res. 2020, 14:151-6. 10.18502\/ijhoscr.v14i3.3722","journal-title":"Int J Hematol Oncol Stem Cell Res"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1060912","article-title":"Co-management strategies for acute myeloid leukemia patients in the community setting","volume":"12","author":"Benton C","year":"2022","unstructured":"Benton C, Grunwald MR, Safah H, Kasner M. Co-management strategies for acute myeloid leukemia patients in the community setting. Front Oncol. 2022, 12:1060912. 10.3389\/fonc.2022.1060912","journal-title":"Front Oncol"},{"key":"ref25","unstructured":"Acute myeloid leukaemia (AML) statistics. Cancer Research UK. Accessed. February 24, 2026: https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/leukaemia-aml."},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.emc.2014.04.005","article-title":"Pediatric oncologic emergencies","volume":"32","author":"Prusakowski MK","year":"2014","unstructured":"Prusakowski MK, Cannone D. Pediatric oncologic emergencies. Emerg Med Clin North Am. 2014, 32:527-48. 10.1016\/j.emc.2014.04.005","journal-title":"Emerg Med Clin North Am"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/471631-feasibility-of-outpatient-follow-up-after-high-dose-cytarabine-consolidation-in-patients-with-acute-myeloid-leukemia","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T08:01:15Z","timestamp":1775462475000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/471631-feasibility-of-outpatient-follow-up-after-high-dose-cytarabine-consolidation-in-patients-with-acute-myeloid-leukemia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,6]]},"references-count":26,"URL":"https:\/\/doi.org\/10.7759\/cureus.106502","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,6]]}}}